Matrix Partners China’s Ran Geng and MRL Ventures Fund’s Christine Brennan invest in a biopharmaceutical company co-founded and led by Hong Wan that is seeking to use the power of innate and adaptive immunity to fight cancer. Matrix Partners China and MRL Ventures took part in Tallac Therapeutics, Inc.’s $62 million Series A round, which also included venBio Partners, Morningside Venture Partners and Lightstone Ventures.
Based in Burlingame, Calif., Tallac will look to use the capital to advance the discovery and development of immunotherapy candidates for multiple solid tumor malignancies. The company’s pipeline of immunotherapies are derived from its novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform. Toll-like receptor agonists are a class of immunotherapy that may produce more robust and durable anti-cancer immunity.
Hong founded the company in 2018 with Jaume Pons, Curt Bradshaw and Corey Goodman, who is a managing partner at venBio. Hong was previously chief scientific officer of ALX Oncology and also held leadership roles at Pfizer and Wyeth Research.
Ran is a venture investor with Matrix Partners China. She has led or is involved in investments in Nikang Therapeutics, InventisBio, Rootpath, Chameleon Bio, and Peijia Medical, which is publicly traded.
Christine is a partner with MRLV and is also on the board of Entrada Therapeutics. She is also an observer on the board of Translate Bio, which is publicly traded, and was on the board of Alector, Inc., which went public last year. Christine joined MRLV in 2017 from Novartis Venture Fund.
Both Ran and Christine are on Tallac’s board.